GMAB vs RPRX
Genmab A/S and Royalty Pharma plc, both Healthcare
Royalty Pharma plc is the larger company at $39B against $33B. On trailing earnings GMAB has the lower P/E of the two, 33.2 against 44.9. RPRX keeps 57 cents of operating profit from each dollar of sales against 29 for GMAB, and GMAB grew sales faster over the last year, +19% against +11%. Over the past year RPRX returned +81% against +75% for GMAB.
| Figure | GMAB | Both figures drawn to one scale | RPRX |
|---|---|---|---|
| Last close | $50.98 | $68.68 | |
| Market cap | $33B | $39B | |
| Trailing P/Eshare price over earnings per share | 33.2 | 44.9 | |
| Revenue growthlast twelve months on the year before | +19% | +11% | |
| Operating margin | 29% | 57% | |
| Net margin | 26% | 26% | |
| Free cash flow yield | 3.5% | n/a | |
| Net cashcash minus all debt | $3.6B net debt | $8.0B net debt | |
| Insiders, 12 monthsopen-market Form 4 trades | n/a | sold $93M net | |
| 1-year return | +75% | +81% | |
| 5-year return | +9.6% | +95% |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher number in each row, nothing more.
Genmab A/S
Revenue of $2.1B in the quarter to Dec 31, 2025, net income $432M.
Royalty Pharma plc
Revenue of $690M in the quarter to Sep 30, 2026, net income $145M. Its largest reported line is Financial Royalty Assets, 95% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.